Ming Liu1, Guang-Liang Huang1, Ming Xu1, Fu-Shun Pan1, Ming-de Lu2, Ke-Guo Zheng3, Ming Kuang2, Xiao-Yan Xie1. 1. a Department of Medical Ultrasonics , Institute of Diagnostic and Interventional Ultrasound of the First Affiliated Hospital, Sun Yat-Sen University , Guangzhou , People's Republic of China. 2. b Department of Hepatobiliary Surgery , Institute of Diagnostic and Interventional Ultrasound of the First Affiliated Hospital, Sun Yat-Sen University , Guangzhou , People's Republic of China. 3. c Department of Radiology of the First Affiliated Hospital , Sun Yat-Sen University , Guangzhou , People's Republic of China.
Abstract
AIM: This study aimed to compare the local therapeutic efficacy of percutaneous thermal ablation for colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC). METHODS: One hundred sixty-one CRLM nodules in 101 patients and 122 HCC nodules in 97 patients were treated with thermal ablation. Complications and local efficacy were retrospectively compared. RESULTS: Major complications were observed in two (2.0%) patients in the CRLM group and one (1.0%) in the HCC group (p = 1.000). The complete ablation (CA) rate of lesions ≤ 3 cm was lower in the CRLM group than in the HCC group (p = 0.018). After a mean follow-up period of 21.1 ± 20.7 months in the CRLM group and 22.1 ± 17.6 months in the HCC group, the local tumour progression (LTP) rate of lesions > 3 cm was higher in the CRLM group than in the HCC group (p = 0.036). The multivariate analysis revealed that only safety margin (≤ 0.5 cm/> 0.5 cm) was a significant predictor of LTP in both CRLM and HCC. CONCLUSIONS: To achieve better local tumour control, thermal ablation should be more aggressive for CRLM than for HCC, especially for large tumours in clinical.
AIM: This study aimed to compare the local therapeutic efficacy of percutaneous thermal ablation for colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC). METHODS: One hundred sixty-one CRLM nodules in 101 patients and 122 HCC nodules in 97 patients were treated with thermal ablation. Complications and local efficacy were retrospectively compared. RESULTS: Major complications were observed in two (2.0%) patients in the CRLM group and one (1.0%) in the HCC group (p = 1.000). The complete ablation (CA) rate of lesions ≤ 3 cm was lower in the CRLM group than in the HCC group (p = 0.018). After a mean follow-up period of 21.1 ± 20.7 months in the CRLM group and 22.1 ± 17.6 months in the HCC group, the local tumour progression (LTP) rate of lesions > 3 cm was higher in the CRLM group than in the HCC group (p = 0.036). The multivariate analysis revealed that only safety margin (≤ 0.5 cm/> 0.5 cm) was a significant predictor of LTP in both CRLM and HCC. CONCLUSIONS: To achieve better local tumour control, thermal ablation should be more aggressive for CRLM than for HCC, especially for large tumours in clinical.
Authors: Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink Journal: Curr Oncol Rep Date: 2022-03-17 Impact factor: 5.945